Location: United States
Total raised: $165M
Funding Rounds 1
| Date | Series | Amount | Investors |
| 24.12.2025 | Series A | $165M | Third Rock... |
Mentions in press and media 3
| Date | Title | Description |
| 24.12.2025 | Syremis Therapeutics Launches With $165 Million Series A Funding To Advance New Schizophrenia And Depression Drug Programs | Syremis Therapeutics, a clinical-stage biopharmaceutical company focused on mental health, has launched with $165 million in Series A financing to advance a neuropsychiatric pipeline rooted in clinically validated biology. The round was co-... |
| 19.12.2025 | Syremis Therapeutics Raises $165M in Series A Financing | Syremis Therapeutics, a Tel Aviv, Israel, and Boston, Massachusetts-based clinical-stage biopharmaceutical company developing novel medicines for the treatment of mental health, launched with $165m Series A financing. The round was co-led b... |
| - | Syremis Therapeutics | “Syremis Therapeutics is a clinical-stage biopharmaceutical company developing novel medicines to make a profound impact on the treatment of mental health.” |